Pediatric Epilepsy Study
A Multicenter, Rater-blind, Randomized, Age-stratified, Parallel-group Study Comparing Two Doses of Oxcarbazepine as Adjunctive Therapy in Pediatric Patients With Inadequately-controlled Partial Seizures.
1 other identifier
interventional
132
4 countries
30
Brief Summary
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Jun 2002
30 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2002
CompletedFirst Submitted
Initial submission to the registry
December 30, 2002
CompletedFirst Posted
Study publicly available on registry
January 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2004
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2004
CompletedNovember 23, 2011
November 1, 2011
2 years
December 30, 2002
November 22, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
change in seizure frequency/24 hours (during the last 72 hours in the Treatment Phase compared to Baseline)
Secondary Outcomes (1)
% change in seizure frequency/24 hours; change in seizure frequency/24 hours; response to treatment (at least a 50%, 75%, or 100% reduction seizure frequency/24 hours).
Interventions
Eligibility Criteria
You may qualify if:
- Have a diagnosis of partial seizures
- Be willing to be hospitalized
- Weigh a minimum of 6.6 pounds
- Be taking a stable dose of one to two concomitant anti-epileptic medications
- Have had a previous CAT scan/MRI confirming the absence of space occupying lesions or progressive neurological disease
- Have normal laboratory results
You may not qualify if:
- Seizures caused by metabolic disturbance, toxic exposure, or active infection
- A primary diagnosis of generalized epilepsy (exception - secondarily generalized seizures)
- A history of status epilepticus within 30 days
- Seizures not related to epilepsy
- Frequent use of additional anti-epileptic medications to treat increases in seizures (for example: rectal diazepam)
- Taking felbamate within 6 months
- Serum sodium levels \<135 mEq/L
- Significant heart, breathing, kidney, stomach, liver, blood, or cancer disorder requiring treatment/therapy
- A history of chronic infection (e.g., hepatitis or HIV)
- Significant electrocardiogram (ECG) abnormalities
- A nursing mother taking anti-convulsant drugs
- Previously demonstrated sensitivity/allergic reaction to Trileptal or related compounds
- Used experimental medication within 30 days of entering this study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (30)
Unknown Facility
Birmingham, Alabama, 35233, United States
Unknown Facility
Mobile, Alabama, 36693, United States
Unknown Facility
Los Angeles, California, 90027, United States
Unknown Facility
Los Angeles, California, 90095, United States
Unknown Facility
Madera, California, 93638, United States
Unknown Facility
Orange, California, 92868, United States
Unknown Facility
Wilmington, Delaware, 19806, United States
Unknown Facility
Miami, Florida, 33155, United States
Unknown Facility
Tampa, Florida, 33607, United States
Unknown Facility
Atlanta, Georgia, 30342, United States
Unknown Facility
Boise, Idaho, 83712, United States
Unknown Facility
Ann Arbor, Michigan, 48109, United States
Unknown Facility
Duluth, Minnesota, 55805, United States
Unknown Facility
Saint Paul, Minnesota, 55102, United States
Unknown Facility
Chesterfields, Missouri, 63017, United States
Unknown Facility
Buffalo, New York, 14222, United States
Unknown Facility
New York, New York, 10016, United States
Unknown Facility
New York, New York, 10032, United States
Unknown Facility
Akron, Ohio, 44308, United States
Unknown Facility
Cincinnati, Ohio, 45229, United States
Unknown Facility
Cleveland, Ohio, 44106, United States
Unknown Facility
Portland, Oregon, 97201, United States
Unknown Facility
Philadelphia, Pennsylvania, 19104, United States
Unknown Facility
Fort Worth, Texas, 76104, United States
Unknown Facility
Houston, Texas, 77030, United States
Unknown Facility
Norfolk, Virginia, 23507, United States
Brigadeiro Hospital
Sao Paulo - SP, 01401-901, Brazil
Unknown Facility
Kehl-Kork, 77694, Germany
Unknown Facility
Kiel, 24105, Germany
Novartis
Mexico City, Mexico
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 30, 2002
First Posted
January 1, 2003
Study Start
June 1, 2002
Primary Completion
June 1, 2004
Study Completion
June 1, 2004
Last Updated
November 23, 2011
Record last verified: 2011-11